Dynavax Technologies Inc. (DVAX) stock rises during pre-market trading. Here’s to why?

0
547
AYTU Stock
AYTU Stock

Dynavax Technologies Inc. (NASDAQ: DVAX) stock surged by 8.07% at last close while the DVAX stock price rises by (5.24% in the pre-market trading session. Dynavax is a biopharmaceutical business in the commercial stage that is researching and monetizing new vaccines. HEPLISAV-B, the company’s first commercial medication, is licensed in the United States and the European Union for the treatment of hepatitis B virus infection generated by all known subtypes in people aged 18 and above.

>> 7 Top Picks for the Post-Pandemic Economy << 

DVAX stock’ Update

Dynavax Technologies and Medigen Vaccine Biologics which is a pharmaceutical firm specializing in the research and manufacture of vaccines and biologics have announced the launch of MVC-COV1901, a COVID-19 vaccine. This week, about 600,000 individuals are expected to receive the Medigen vaccination.


China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored


Read More

MVC acquired Taiwan Emergency Use Authorization and clearance in July to include MVC-COV1901 in Taiwan’s COVID-19 vaccine vaccination program. MVC COVID-19 vaccine is recommended for people over the age of 20 and is given in two doses 28 days apart for COVID-19 protection. MVC shall provide a monthly safety management plan throughout the declared EUA period, and a vaccination efficacy report within one year of receiving EUA approval, according to the Advisory Committee.

Official Statements

Charles Chen, Chief Executive Officer at Medigen stated,

Medigen is grateful for the opportunity to assist the Taiwanese people and contribute to the worldwide response to the epidemic. They were thankful to the Taiwan FDA for granting emergency use authorization, and they appreciate the time and effort put in by both the TFDA personnel and the experts who attended the risk and benefit analysis conference. It’s encouraging to see a positive outcome from the Medigen team’s tireless efforts.

Ryan Spencer, Chief Executive Officer of DVAX stock stated,

They are delighted to announce that Medigen’s vaccination is now available to Taiwanese citizens. They’re really happy about this first EUA and approval for COVID-19 vaccines with CpG 1018 adjuvant, which they believe will be the start of many. They feel that adjuvanted vaccines can make a substantial contribution to current immunization efforts, given the limitations of existing vaccines and the worldwide vaccine deficit.

LEAVE A REPLY

Please enter your comment!
Please enter your name here